Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Li X, et al. Among authors: d agostin d, dwyer d. J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216. J Bone Miner Res. 2008. PMID: 18269310 Free article.
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ. Ominsky MS, et al. Among authors: dwyer d. J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109. J Bone Miner Res. 2008. PMID: 18433301 Free article.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. Among authors: dwyer d. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581 Free article.
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.
Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. Ominsky MS, et al. Among authors: dwyer d. J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215. J Bone Miner Res. 2009. PMID: 19257823 Free article.
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Ominsky MS, et al. Among authors: dwyer d. J Bone Miner Res. 2011 May;26(5):1012-21. doi: 10.1002/jbmr.307. J Bone Miner Res. 2011. PMID: 21542004 Free article.
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Li X, et al. Among authors: dwyer d. Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5. Endocrinology. 2011. PMID: 21733832
1,180 results